New study probes Glucagon's hidden role in blood sugar after gastric bypass
NCT ID NCT07212868
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the hormone glucagon influences blood sugar in people who have had bariatric surgery and those who haven't. Researchers will use an experimental drug called REMD-477 to block glucagon and measure changes in glucose metabolism. The goal is to better understand why some people develop blood sugar problems after surgery. The study involves 150 adults aged 18 to 65 who are non-diabetic.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- REMD-477 (a monoclonal antibody that blocks glucagon) and glucagon infusion
- What this could lead to
- If successful, this study could help explain why some people develop diabetes after bariatric surgery and point toward new treatments.
- What could go wrong
- This is an early-phase study with only 150 participants, so results may not apply to everyone. The drug REMD-477 is investigational and not yet FDA-approved.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-DIABETIC are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Diabetes Institute - University Health System
RECRUITINGSan Antonio, Texas, 78207, United States
-
University of Texas San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.